Demant stock
Price history
+63.08% over the period1 year: from kr 214.00 (November 17, 2025) to kr 349.00 (November 16, 2026), +63.08%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 349.00 |
| October 30, 2026 | kr 365.40 |
| September 30, 2026 | kr 310.00 |
| August 31, 2026 | kr 288.60 |
| July 31, 2026 | kr 281.00 |
| June 30, 2026 | kr 268.20 |
| May 29, 2026 | kr 250.20 |
| April 30, 2026 | kr 202.00 |
| March 31, 2026 | kr 193.90 |
| February 27, 2026 | kr 196.80 |
| January 30, 2026 | kr 220.40 |
| December 30, 2025 | kr 215.20 |
| November 28, 2025 | kr 219.20 |
| November 17, 2025 | kr 214.00 |
At a glance
The company
Develops, manufactures and distributes hearing aids, operates hearing care clinics, and provides hearing and balance assessment solutions
Latest results
Quarter to September 30, 2026 · EPS kr 0.00 (estimate kr 0.00)
Next event
TickerLandia's take on Demant
- Pricier than usual relative to earnings: P/E on the latest fiscal year 31 vs a median of 24 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 31 vs 31 (−2%) in a group of 10.
- Strong point: Market momentum (94/100 in its group). Weak point: Financial strength (7/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−9.59% from the 52-week high
Analysts · 20 analysts
Average targetkr 359.85+3.11% vs. price
Buy 9 · Hold 10 · Sell 1 · Buy
TickerLandia Fingerprint: Demant
Compared with similar companies: very strong momentum and very low financial strength.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage56
How much it costs relative to what it produces.
Metric Value Position in group Price/book 6.57 76 P/E (trailing 12 months) 30.5 50 Forward P/E 20.1 48 EV/EBITDA 18.7 68 Price/sales 3.00 37 Profitabilityhigh61
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 17.2% 53 ROE 23.3% 82 Gross margin 76.3% 92 Net margin 6.6% 18 ROA 7.3% 60 Earnings stabilityaverage60
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.9% 63 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthaverage59
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +14.80% 79 Earnings growth (year over year) +6.40% 53 Average revenue growth (3 years) +5.24% 44 Financial strengthvery low7
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 4.17 5 Debt/equitycounts in reverse: lower means more financial strength 1.79 2 Current ratio 0.82 5 Interest coverage 7.18 18 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong94
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +56.20% 91 Distance from 200-day average +34.36% 97 Riskaverage56
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 24.8% 52 Volatility (60 days) 30.0% 61
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Demant is pricier than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Demant's P/E today is 31.2, above the median of its last 10 fiscal years (24.3; between 19.1 and 51.5 from 2016 to 2025). Demant's P/E (trailing 12 months): 30.5, in line with the median of a group of 10 similar companies (31.1).
Compared with 10 similar companies
| Metric | Demant | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 30.5 | Middle | |
| Forward P/E | 20.1 | Middle | |
| Operating margin | 17.2% | High | |
| ROE | 23.3% | High | |
| Debt/equity | 1.79 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Demant. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 12.91B
Latest quarter · Q2 2026
Net income
kr 1.19B
Latest quarter · Q2 2026
Quarterly net margin
9.2%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 73.86B
- P/E
- 30.5
- EPS
- kr 11.48
- Volume
- 684.7K
- Daily trading
- €20.89M
How Demant is changing
All resultsRevenue grew 9.7% a year on average over the last 5 years
Operating margin rose from 15.8% to 17.3%
Profits turn into cash: free cash flow equal to 181% of net income
Returns
Demant returns with dividends
kr 1,000 invested in Demant 5 years ago, on November 16, 2021, would be worth kr 1,045 today with dividends reinvested: +4.49% in total, +0.88% per year. On price alone it would be kr 1,045 (+4.49%).
| Period | Demant | kr 1,000 becomes |
|---|---|---|
| 1 month | −2.73% | kr 973 |
| 6 months | +48.01% | kr 1,480 |
| Year to date | +62.17% | kr 1,622 |
| 1 year | +63.08% | kr 1,631 |
| 3 years | +27.00% | kr 1,270 |
| 5 years | +4.49% | kr 1,045 |
| 10 years | +205.07% | kr 3,051 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Demant: technical analysis
Demant is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 10.5% below its all-time closing high (kr 389.80, August 4, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 46
- Between 30 and 70
- vs 200-session average
- +33.57%
Support and resistance
Price areas where Demant has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last pricekr 349.00
- Supportkr 298.80−14.38%2 touches, last on September 3, 2026
- Supportkr 285.60−18.17%4 touches, last on August 21, 2026
- Supportkr 266.13−23.74%3 touches, last on July 22, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 30.0%
- Largest fall in the last year
- −24.77%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Demant: seasonality
Average monthly price change over 32 years
Over the last 32 years, the strongest month for Demant has been April: +3.93% on average, positive in 23 years out of 31. The weakest has been August: −1.45% on average, positive in 12 years out of 32. November, the current month, has been positive in 16 years out of 31 (+1.98% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.98% | +4.39% | 21 of 31 |
| February | +1.29% | −1.32% | 13 of 31 |
| March | +2.69% | +2.28% | 19 of 31 |
| April | +3.93% | +3.03% | 23 of 31 |
| May | +3.33% | +2.29% | 22 of 31 |
| June | −0.68% | −0.43% | 14 of 32 |
| July | +1.23% | +0.80% | 17 of 32 |
| August | −1.45% | −1.98% | 12 of 32 |
| September | +0.91% | +1.48% | 19 of 32 |
| October | +1.69% | +0.38% | 16 of 32 |
| November | +1.98% | +0.64% | 16 of 31 |
| December | +2.27% | +2.38% | 22 of 31 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Demant and its competitors
Hearing aids are the core of the business of this Danish group, which develops and manufactures them and sells them at wholesale level. Alongside these devices it owns and operates hearing care clinics, where patients are tested and fitted. It also supplies diagnostic tools for testing hearing and balance to professionals such as audiologists, ENT specialists and balance clinics. Its activities reach customers across Europe, North America, Asia, the Pacific region and other markets abroad.
- Headquarters
- Smørum, Denmark
- Employees
- 26,616
- Founded
- 1904
- Chief executive
- Søren Nielsen
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DemantDEMANT | $10.92B | 17.2% | 30.5 | +48.01% |
| Smith & NephewSN. | $13.03B | 14.2% | 21.4 | +5.76% |
| GetingeGETI.B | $7.63B | 14.3% | 27.1 | +49.29% |
| SectraSECT.B | $6.17B | 20.6% | 99.9 | +27.79% |
| Sonova HoldingSOON | $20.24B | 19.5% | 31.7 | +61.25% |
| Koninklijke PhilipsPHIA | $29.64B | 8.8% | 66.9 | +26.10% |
Same industry or related industries, similar size. Compare Demant with its competitors · Full profile
